Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium-glucose cotransport 2 (SGLT2) ...

Providers need to assess the benefit-risk profile of SGLT2 inhibitors for individual patients, and take steps to avoid unnecessary risks. Sodium glucose cotransporter 2 (SGLT2) inhibitors provide ...

Adults with type 2 diabetes treated with an SGLT2 inhibitor had roughly a third fewer episodes of acute kidney injury (AKI) compared with matched people with type 2 diabetes treated with a DPP4 ...

New research suggests that a commonly used type of blood pressure medication may be associated with a higher risk of kidney ...

Use of SGLT-2 inhibitor therapy at admission was associated with a 32% reduced risk for acute kidney injury (AKI) in hospitalised patients, and this benefit was maintained when therapy was continued ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — SGLT2 inhibitors reduce the risk and progression of chronic kidney disease and AKI regardless of ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...

SGLT2 inhibitor use was also significantly associated with a 1.6-, 1.7-, and 1.7-fold increased risk of UTIs compared with DPP-4 inhibitors, sulfonylurea, and thiazolidinedione, respectively, the ...